Westfield Capital Management
ARQT icon

Westfield Capital Management’s Arcutis Biotherapeutics ARQT Stock Holding History

Westfield Capital Management’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-680,374
Closed -$10.1M – 225
2022
Q4 		$10.1M Buy
680,374
+210,600
+45% +$3.68M 0.08% 173
2022
Q3 		$8.98M Buy
+469,774
New +$10.6M 0.07% 178

Other funds holding ARQT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Westfield Capital Management's ARQT Position: Q1 2023 in Review

Westfield Capital Management sold out of Arcutis Biotherapeutics (ARQT) in Q1 2023, closing a stake of 680,374 shares — an estimated $10.1M sold.

Westfield Capital Management first reported a position in ARQT in Q3 2022 and held it in 2 quarters. The position peaked at $10.1M in Q4 2022. 143 funds tracked by Wall St. Rank hold ARQT as of Q1 2023.

  • Westfield Capital Management reported no remaining Arcutis Biotherapeutics position as of Q1 2023 after selling out during the quarter.
  • Westfield Capital Management sold 680,374 Arcutis Biotherapeutics shares in Q1 2023, an estimated $10.1M.
  • Westfield Capital Management first reported a position in Arcutis Biotherapeutics in Q3 2022 and held it in 2 quarters.
  • Westfield Capital Management's Arcutis Biotherapeutics position peaked at $10.1M in Q4 2022.
  • 143 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q1 2023.

Based on Westfield Capital Management's 13F filing for Q1 2023, filed 12 May 2023.